Please login to the form below

Not currently logged in
Email:
Password:

Bayer president Andreas Fibig set to depart

Will become CEO of International Flavors & Fragrances

Andreas-Fibig-BayerBayer Healthcare's president Andrea Fibig is to leave to become CEO of International Flavors & Fragrances (IFF).

Fibig has served as president of Bayer Healthcare since 2008, during which time he has been head of the company's pharmaceuticals division and a member of the executive committee.

The appointment at IFF marks a departure for Fibig who has been in the pharma industry since the early 1980s, serving at Schering and Boehringer Ingelheim in his early years.

In 2000 he went on to serve as present of Pharmacia & Upjohn's operations in Germany before joining Pfizer as president for its operations in Latin America, Africa and the Middle East and then serving as senior VP and general manager for Pfizer in the US.

This experience in the US will benefit Fibig in his first CEO position as he takes over from Doug Tough at New York-based IFF, which develops and creates flavors and fragrances for consumer products.

Tough commented that Fibig “brings the right combination of experience and skills”.

“He has led businesses with an international footprint similar to ours, has firsthand experience in key emerging markets where we see further opportunity, and understands the critical importance of science-based research in driving innovation and competitiveness,” he added.

Tough also remarked that Fibig knows IFF well due to serving as a board member since 2011.

As for who will replace Fibig at Bayer, the company stated a successor will be announced “in a few days”.

29th May 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....